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The limited predictive value of semen analysis in achieving natural conception or in IVF outcome confirms the need for sperm
function tests to determine optimal management. We reviewed HZA and SPA predictive power in IVF outcome, with statistical
significance of diagnostic power of the assays. HZA was readily efficient in predicting IVF outcome, while evident inconsistency
among the studies analysed framed the SPA’s role in male fertility evaluation. Considerable variation was noted in the diagnostic
accuracy values of SPAwith wide sensitivity (52–100%), specificity (0–100%), and PPV (18–100%) andNPV (0–100%) together with
fluctuation and notable differentiation in methodology and cutoff values employed by each group. HZA methodology was overall
consistent with minor variation in cutoff values and oocyte source, while data analysis reported strong correlation between HZA
results with IVF outcome, high sensitivity (75–100%), good specificity (57–100%), and high PPV (79–100%) and NPV (68–100%).
HZA correlated well with IVF outcome and demonstrated better sensitivity/specificity and positive/negative predictive power.
Males with normal or slightly abnormal semen profiles could benefit by this intervention and could be evaluated prior to referral to
assisted reproduction. HZA should be used in a sequential fashion with semen analysis and potentially other bioassays in an IVF
setting.
1. Introduction
Male fertility is considered to be affected by genetic disorders,
congenital or acquired urogenital abnormalities, varicocele,
infection, endocrine disturbances, immunological and/or
lifestyle factors, environmental assaults, and idiopathic fac-
tors with no demonstrable aetiology [1]. Fifteen percent of
all couples of reproductive age are affected by infertility [2],
with male factor being solely responsible in about 20% of
these and a contributory factor in another 30%–40% [3]. The
latter together with the lasting debate over sperm quality
and density decline [4–7] intensifies the need for accurate
and rapid evaluation of sperm function in assisting clinical
decisions, that is, whether natural conception is feasible or
medical support should be sought for reproduction, taking
the age of the woman and the duration of infertility into
account.
Semen analysis is the basis of primary male investigation,
and in certain cases, such as in severe oligozoospermia,
semen parameters are of absolute importance and should be
strongly considered in clinical management by implementing
the World Health Organization (WHO) and the European
Society of Human Reproduction and Embryology (ESHRE)
guidelines and recommendations [8]. However, the limited
predictive value of semen analysis in achieving natural con-
ception or in assisted reproductive technology (ART)
outcome such as in in vitro fertilization (IVF) [9–12] confirms
the need for sperm function tests, as well as in cases of oli-
goasthenoteratozoospermia or idiopathic infertility when
2 BioMed Research International
knowledge of sperm functional capacity is a requisite for
determining optimal management.
The sperm penetration assay (SPA) was introduced by
Yanagimachi et al. [13] and involved the use of surrogate ova
from golden hamsters, stripped of the zona pellucida to allow
interspecies interaction. SPA evaluates sperm function capac-
ity by examining sperm competence in distinct biological
processes required for fertilization; capacitation, acrosome
reaction, spontaneous recognition of and fusionwith vitelline
membrane to the end-point of chromatin decondensation
[13]. The outcome of this assay is hamster oocyte penetra-
tion rate expressed as the percentage of ova with positive
penetration divided by the total number of ova, in control
and test samples (supplemental Figure 1 (see supplemen-
tal Figure 1 in Supplemntary Material available online at
http://dx.doi.org/10.1155/2013/945825)). Positive penetration
is confirmed through the presence of swollen sperm head
with a visible tail or male pronucleus, through microscopical
examination of the ooplasm. Correspondingly, the concept of
sperm-zona pellucida binding assay was first introduced by
Liu et al. [14], who pioneered the competitive zona binding
(CBZ) test, and Burkman et al. [15] who established the
hemizona assay (HZA) the same year. Franken et al. [16]
described salt storaging of human oocytes, while Morroll
et al. [17] initiated the utilization of cryostored oocytes for
this assay. HZA is a functional homologous model of gamete
interaction that uses nonviable, bisected human oocytes to
examine spermatozoa capacity to bind to glycoprotein recep-
tors ZP3/ZP4 on the zona surface and undergo activation
and acrosome reaction in an appropriate timed manner. The
main principle of this assay is the assessment of sperm-
zona binding in vitro and its numerical interpretation by the
calculation of the hemizona assay index (HZI) value (supple-
mental Figure 2). It has been estimated that defective sperm-
zona binding and zona penetration are among the most
common causes of fertilization failure and that within the
oligozoospermic population around 80% of males produce
spermatozoa that are unable to interact normally with zona
pellucida [18–21]. Both SPA and HZA have the potential to
represent male fertility indicators, as both techniques reflect
certain biological requisites for reproduction; a sequence of
functional conditions is required for the sperm to interact and
fuse with the ovum.
The validity of any diagnostic test is based on a set of
criteria according to ESHRE: sensitivity (to produce few false-
negatives), specificity (to produce few false-positives), com-
plexity, time, and cost effectiveness, and positive (PPV) and
negative (NPV) predictive values (in terms of fertility and
fertilization rates) [9]. The aim of the present study was
to review and appraise the published evidence to date on
two major techniques: SPA and HZA. We reviewed their
predictive power in IVF outcome and performed an assay
overview in terms of protocol standardization, to determine
whether these tests could be incorporated in routine male
fertility assessment and whether they could be used as a tool
for predicting fertilization potential.
2. Materials and Methods
2.1. Search Strategy. This systematic review was conducted
according to the PRISMA guidelines [22] and the initial
protocol agreed by all authors. Studies in English language
from 1976 to August 2012 were compiled with no study
design restrictions, using the following search algorithms in
two major scientific/medical databases (Medline/PubMed,
ScienceDirect):
(i) “sperm penetration assay” OR “SPA” OR “HEPT”
OR “ZHEPT” OR “HEPA” OR “HOPT” OR “hamster
test” AND “IVF” OR “in vitro fertilization” OR “in
vitro fertilisation” OR “assisted reproduction” OR
“Reproductive Techniques, Assisted” OR “ART”
(ii) “hemizona assay” OR “HZA” OR “sperm zona test”
AND “IVF” OR “in vitro fertilization” OR “in vitro
fertilisation” OR “assisted reproduction” OR “Repro-
ductive Techniques, Assisted” OR “ART”.
Search results were confirmed through the SCIRUS database.
There were no MeSH terms assigned to the specific assays.
Reference lists of relevant articles were hand-searched for
potentially eligible studies.
2.2. Screening. Tominimize bias (extraction, recording, con-
formity, and retrieval), three authors (P. Vogiatzi, C. Siris-
tatidis, and M. Creatsa) performed the primary evaluation
of titles and abstracts identified through the publication
identification process, and each author provided a list of
potentially eligible studies. Those three authors extracted the
data independently, using a preagreed data extraction form.
Collected data included general information (title, author,
year, journal, and clinical setting), study characteristics
(design, inclusions/exclusions), participants’ characteristics
(cause and duration of preexisting infertility, semen parame-
ters, and protocols for ovarian stimulation), assay parameters
(SPA/HZA and fertilization rate cutoff values, different cul-
ture media and sperm enhancers used, incubation lengths,
hemizona sources, and preservation methods), and results
(number of participants, reference population, specificity and
sensitivity of the assay, and PPV and NPV as reported or
calculated by the data sets provided by the study group). If
multiple publications using the same cohort were identified,
the most recent or more complete publication was used for
data extraction. Two authors (P. Vogiatzi and C. Siristatidis)
performed the final selection of the potential eligible studies;
conflicts were resolved by team consensus.
2.3. Eligibility. Studies comparing HZA and SPA results
with outcome parameters in an IVF setting were consid-
ered to examine the validity of these tests. Studies had to
be published in a scientific/medical journal and be easily
accessed through electronic means or retrieved through a
printed library version. Case series/reports, animal studies,
or articles published on independent websites were excluded.
Modifications in methodology that greatly deviate from the
conventional protocol and interventions that could interfere
with the results were also weighed up. Statistical analysis
methods and presented data were also taken into account,
in terms of providing sensitivity/specificity and PPV/NPV
or otherwise reporting the appropriate data sets in order to
calculate these values and determine the resulting diagnostic
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Figure 1: PRISMA flow diagram of study inclusion process.
accuracy, since these are the parameters that define the
validity of diagnostic tests according to ESHRE [9]. Eligible
studies were excluded for the following reasons: protocols
including pre-treatments or interventions that could affect
the results, studies with other than fertilization rate as a
primary outcome or through natural conception and other
assisted conception techniques (intrauterine insemination-
IUI, intracytoplasmic sperm injection-ICSI, subzonal sperm
insemination-SUZI), and essential data for diagnostic accu-
racy not shown and grouped data for true positives/negatives
and false- positives/negativesmissing.Where applicable, data
was analyzed as published by each study group; reevalua-
tions were not included. Reported oocyte immaturity and
laboratory/equipment failurewere disregarded if these results
were already incorporated in the presented data.Theoutcome
measure was fertilization outcome through IVF compared
to SPA/HZA results with statistical significance by reporting
specificity, sensitivity, PPV, and NPV values for diagnostic
power of the assays.
3. Results
The initial search yielded 2551 potentially relevant studies
that were reduced to 1659 by removing duplicates (Figure 1).
All titles and abstracts were screened to exclude irrelevant
publications, resulting in 52 potentially eligible studies. The
full-text articles were assessed, and 21 manuscripts (14 on
SPA and 7 on HZA) were identified to provide data cor-
responding to the research question [23–43]. Characteris-
tics of the studies included publication date, study design,
and size as well as patient characteristics and experimental
interventions (capacitation medium type and pre-incubation
lengths/oocyte source and preservation means) which are
presented in Tables 1(a) and 1(b), for SPA and HZA, respec-
tively. Assay methodology researched in this review has been
presented in supplemental Figures 1 and 2, for SPA and HZA,
respectively. There were no limitations in participants’ age,
and fertility status was either unknown or defined through
conventional semen analysis (hereby reported as normal/
abnormal semen parameters), while control groups consisted
of sperm samples from donors with proven fertility and
normal semen parameters. A summary of assay and fertil-
ization rate cutoff values, along with sensitivity/specificity,
PPV/NPV, are presented in Tables 2 and 3, for SPA and HZA,
respectively. Statistical values were either extracted from the
manuscripts or calculated through the reported values to
provide the diagnostic accuracy parameters for each test.
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Table 1: (a) Experimental parameters of studies investigating the validity of SPA. (b) Experimental parameters of studies investigating the
validity of HZA.
(a)
Study group Publication date Study design 𝑛 Normal SP(𝑛)
Abnormal SP
(𝑛) Capacitation medium Pre-incubation period
Margalioth et al.
[23] 1983 Prospective 20 20 0 NR NR
Wolf et al. [24] 1983 Prospective 24 24 0 Ham’s F-10 with 7,5%maternal serum 3 hrs
Foreman et al. [25] 1984 Prospective 22 14 8 Earle’s with 8% HSA 3 hrs
Ausmanas et al.
[26] 1985 Prospective 54 42 12
BWWwith 35mg/mL
HSA 5 hrs
Belkien et al. [27] 1985 Prospective 29 23 6 Ham’s F-10 with 10%maternal serum 6 hrs
Margalioth et al.
[28] 1986 Prospective 134 124 10
mBWWwith
35mg/mL HSA 18 hrs
Corson et al. [29] 1987 Prospective 30 17 13 BWWwith 5mg/mLHSA 18–20 hrs
Kruger et al. [30] 1988 Retrospective 84 NR NR NR NR
Coetzee et al. [31] 1989 Prospective 71 NR NR BWW 18–20 hrs
Ibrahim et al. [32] 1989 Prospective 59 35 24 BWWwith3.5mg/mL HSA 3 hrs
Nahhas and
Blumenfeld [33] 1989 Prospective 31 27 4
BWWwith 36mg/mL
HSA 18 hrs
McClure et al. [34] 1990 Prospective 19 10 9 BWWwith 6mg/mLHSA 18 hrs
0.4mL of Human
Follicular Fluid 0.5 hrs
Soffer et al. [35] 1992 Follow-up 241 NR NR TEST yolk buffer 18–22 hrs
Freeman et al. [36] 2001 Prospective 216 NR NR BWWwith TESTyolk buffer 18–20 hrs
Abbreviations: 𝑛 (number of participants/patients), SP (Semen Parameters), BWW (Biggers, Whitten andWhittinghammedium), HSA (Human Serum
Albumin), NR (Not Reported).
(b)
Study group Publication date Study design 𝑛 Normal SP (𝑛) Abnormal SP (𝑛) Oocyte source Oocytepreservation
Oehninger et al.
[37] 1989 Prospective 28 17 11 SR ovarian tissue Salt storage
Oehninger et al.
[38] 1991 Prospective 37 15 22 IVF patient donation Salt storage
Oehninger et al.
[39] 1992 Prospective 44 31 13 SR ovarian tissue Salt storage
Franken et al. [40] 1993 Prospective 112 58 54 SR ovarian tissue andIVF patient donation Salt storage
Franken et al. [41] 1993 Prospective 48 28 20 SR ovarian tissue andIVF patient donation Salt Storage
Gamzu et al. [42] 1994 Prospective 65 47 18 IVF patient donation Salt Storage
Oehninger et al.
[43] 1997 Prospective 196 138 58 SR ovarian tissue Salt storage
Abbreviations: 𝑛 (number of participants/patients), SP (Semen Parameters), SR (Surgically Recovered).
The addressed usefulness and validity of SPA were
presented with major discrepancies in protocols, statistical
analysis, and outcome. The inconsistencies in capacitation
medium type and incubation lengths in SPA methodology
are illustrated in Table 1(a). Protocol variation across studies
was evident in the range of SPA cutoff values used (Table 2),
final sperm concentration for the assay ranging from 0.4 to
20 × 106/mL, in contrast to the suggested 5 × 106 by the
WHOmanuals [44] and spermpreparationmethods [45, 46].
Second and third generation SPA promoted the addition of
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Table 2: SPA and IVF outcome and summary of diagnostic accuracy findings.
Study group, date SPA threshold (%) Fertilization rate cut-off (%) Sensitivity Specificity PPV NPV
Margalioth et al., 1983 [23] ≥20 >0 100% 70% 77% 100%
Wolf et al., 1983 [24] ≥10 >0 88% 0% 68% 0%
Foreman et al., 1984 [25] >10 >0 67% 53% 18% 91%
Ausmanas et al., 1985 [26] >15 >0 73% 33% 95% 7%
Belkien et al., 1985 [27] >15 >0 87% 17% 80% 25%
Margalioth et al., 1986 [28] >20 >0 94% 57% 85% 78%
Corson et al., 1987 [29] ≥11 >0 52% 100% 100% 39%
Kruger et al., 1988 [30] >10 >0 59% 62% 82% 33%
Coetzee et al., 1989 [31] >10 >0 65% 85% 95% 35%
Ibrahim et al., 1989 [32] >17 >0 74% 84% NR NR
Nahhas and Blumenfeld,
1989 [33] >20 >0 100% 44% 81% 100%
McClure et al. 1990 [34] >10 >0 93% 75% 93% 75%
Soffer et al., 1992 [35] >20 >0 96% NR 82% 74%
Freeman et al., 2001 [36] ≥20 >50 70% 99% 98% 84%
Abbreviations: PPV (positive predictive value), NPV (negative predictive value), and NR (not reported).
Table 3: HZA and IVF outcome and summary of diagnostic accuracy findings.
Study group, date HZI threshold (%) Fertilization rate cutoff (%) Sensitivity Specificity PPV NPV
Oehninger et al., 1989 [37] >36 >65 83% 95% 83% 95%
Oehninger et al., 1991 [38] >36 >65 80% 100% 100% 85%
Oehninger et al., 1992 [39] >35 >65 100% 61% 79% 100%
>0 90% 57% 82% 73%
Franken et al., 1993 [40] >30 >50 84% 72% 85% 70%
Franken et al., 1993 [41] >30 >55 75% 75% 81% 68%
Gamzu et al., 1994 [42] >23 >66 100% 94% 85% 100%
Oehninger et al., 1997 [43] >30 >60 93% 73% 85% 87%
Abbreviations: HZI (hemizona index), PPV (positive predictive value), and NPV (negative predictive value).
mild enhancers, hyperosmotic medium, albumin, follicular
fluid, TEST yolk buffer, calcium ionophore, progesterone, and
pentoxyfline, at variable concentrations and preincubation
lengths (0.5 to 22 hours), so as to enhance sperm parameters
and achieve capacitation prior to assay. This enabled the
examination of different approaches that could contribute
in assay improvement but rendered great interlaboratory
inconsistency and ambiguous results over efficiency. In addi-
tion, the majority of studies did not address neither female
factor and potential oocyte deficiency that could affect IVF
outcome, nor the period of abstinence of the participants.
Analysis of data indicated 7 studies to have presented
SPA results that correlate well with IVF outcome [23, 28,
32–36], indicating this assay to be a valuable prognostic
tool when evaluating sperm function. The drawback is that
these studies fluctuate extensively in specificity (44–100%)
with wide variation in preparation methods, capacitation
medium, preincubation lengths, variation in SPA cutoff
values (10–20%), and fertilization rate cutoff values. Others
have suggested a relative predictive value of SPA at some
level, but data analysis failed to present the anticipated values
to establish this assay as a valuable predictor of fertilization
outcome [24, 26, 29]. Conversely, the clinical relevance of SPA
has been debated, and significant false-positive/negative rates
were demonstrated [25, 27, 31], suggesting that this assay is of
limited predictive value and unreliable for IVF. Furthermore,
Kruger et al. [30] stated that, although a negative SPA might
indicatemale factor infertility, this assay could not be justified
as a better predictor than sperm morphology assessment in
IVF outcome. Other studies that investigated efficacy on a
different setting than the one examined on this review could
not validate SPA as a better predictor than computer assisted
semen analysis (CASA), manual motility scoring, or even
conventional semen analysis [47, 48].
The predictive power of HZA was reviewed along with
possible drawbacks of this technique and protocol standard-
ization.As summarized byYao et al. [49], somedegree of vari-
ation inHZAoutcome could be induced by oocyte source and
preservation method, sperm concentration and preparation
method, base medium and aspiration pipette diameter, and
oocyte microdissection method. Consequently, some modi-
fications of the initial protocol were proposed [16, 17, 50–52].
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Initial testing with a range of HZA cutoff values (15–36%)
did not enable the standardization of a baseline value;
however, some range reduction was later achieved. Patient
characteristics are summarized in Table 1(b), in the form of
normal/abnormal sperm parameters, and the variable oocyte
sources exploited by different studies are demonstrated.
There are variable but limited sources of zonae, including
ovarian tissue from surgical cases or cadavers and noninsem-
inated/unfertilized oocytes donated by IVF patients. In an
attempt to provide an alternative oocyte source for the assay,
species like gibbons and gorillas were investigated in terms of
the oocyte ability to interact with human spermatozoa [53–
55], but this process is highly species specific, and none of
these options was further explored. Subsequently, a major
drawback is the limited availability of human oocytes, a
problem which could be circumvented with the possible
availability of biologically active recombinant human zona as
a substitute, along with other chemical/biological candidates
[56–59].
The predictive value of HZA has been extensively investi-
gated in terms of IVF outcome and the sum of the studies
included in this review served to validate this assay as a
predictor of fertilizing capacity [37–43]. A variable range
of HZI threshold values (23–36%) was noted (most studies
employed either 30% or 36%), and there was some variation
in fertilization rate cutoff values (50–66%) and in oocyte
source, but the analysis of the published data of the selected
studies for this review consistently reported high sensitivity
and specificity, with concomitantly high PPV and NPV
(Table 3). Increased diagnostic accuracy values demonstrated
throughout indicate that in an IVF setting HZA results are
specific to fertility potential, establishing whether spermato-
zoa of the male under investigation are functionally compe-
tent to interact with the oocyte and complete a sequence of
actions essential for fertilization.
4. Discussion
Analysis of the published evidence on the preselected sperm
function tests validity demonstrated inconsistent results on
SPA’s role in male fertility evaluation, while HZA was consis-
tently efficient in predicting IVF outcome. When reviewing
data on SPA, considerable variation was noted in diagnostic
accuracy values with wide sensitivity (52–100%), specificity
(0–100%), and PPV (18–100%) and NPV (0–100%) together
with fluctuation and notable differentiation in methodology
and cutoff values employed by each group. On the other
hand, HZA methodology was overall consistent with minor
variation in cutoff values and oocyte source, while data
analysis reported strong correlation of HZA results with
IVF outcome. These studies consistently reported high HZA
sensitivity (75−100%), good specificity (57–100%), and high
PPV (79–100%) and NPV (68–100%).
On the level of association of SPA with IVF outcome
[23–36], some studies reported good correlation, and others
could not validate any apparent connection, whereas the
rest determined a relative predictive value under specific
conditions. Unsurprisingly, these contrasting views have
brought about uncertainty over the power of this tool in
male fertility assessment. The relevant meta-analyses [60, 61]
confirmed the heterogeneity among studies and overall low
predictive power of SPAon IVFoutcomewith increased false-
positives and, therefore, reduced specificity. In particular,
Mol et al. [60] demonstrated significant heterogeneity of
the assay with low sensitivity (37%) and, interestingly, high
specificity (95%) and concluded that SPA is an inadequate
assay for selecting patients for IVF treatment. Similarly,
Oehninger et al. [61] reported a high false-positive rate and
thus reduced specificity of SPA as a predictor of fertilization,
corroborated also by the European Society of Human Repro-
duction and Embryology [62], which accordingly recom-
mended its abandonment at that point. Comparedwithmuch
simpler approaches, such as spermmotility assessment, strict
morphology, or even conventional seminology, SPA did not
appear to be superior [30, 47, 48]. SPA is still a widely applied
research tool as it examines certain functional aspects, but it
is currently of limited value in clinical practice, since it does
not contribute significant information in male fertility status.
Standardised protocols may provide diagnostic information
with greater precision in terms of sensitivity and specificity,
as well as replicating gamete physiological interaction more
accurately, and this is in agreement with Oehninger et al.
[61] suggesting that SPA methodology should be revisited to
produce a consensus protocol.
HZA has undergone little variation since its introduction
and consistency of methodology are preserved to a great
extent across IVF laboratories. A considerable limitation
in the applicability of the assay is the restricted reserve of
human oocytes [42], although the prospective utilization of
biologically active recombinant human zona pellucida could
circumvent it. Furthermore, the complexity of performing
oocyte dissection into two equal hemispheres requires high
accuracy to avoid the potential risk of differentially exposed
area between control and test samples. Finally, ethical con-
cerns arise over the extent of the allowed gamete interaction
during sperm function assays, although HZA-in contrast
to the CZB-exploits oocytes devoid of ooplasm and its
application could nullify any points of consideration.
In our review, HZA appeared to be an important marker
of spermatozoa fertilizing capacity. It correlatedwell with IVF
outcome, as it demonstrated better sensitivity/specificity and
positive/negative predictive power than SPA, in agreement
with the findings of a previous meta-analysis [61], reporting
high PPV and NPV and consistently low false-negative rates.
The noted result of homogeneity of the included studies,
together with the subtle methodology variation between
laboratories, indicates that HZA is a reliable candidate to
assess sperm function capacity. Males with normal or slightly
abnormal semen profiles could benefit by this intervention
and be evaluated prior to referral to assisted reproduction.
This assay provides essential information on several aspects of
sperm function and could be used in a sequential fashionwith
semen analysis and potentially other bioassays in an ART
setting.
The limitations of the current review reflect the cor-
responding limitations of the individual studies. Although
numerous records were originally retrieved during our
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search, studies that used different assisted conception meth-
ods such as intrauterine insemination (IUI) or ICSI, or with
primary outcomes such as live birth rate, or pregnancy rate
were excluded to preserve consistency over the examined
parameters defining the outcome of each study.This was also
considered in the context of the exact process that reflects
functional capacity of the spermatozoon where fertilization
is the outmost measure compared to pregnancy and live
birth where other factors such as chromosomal integrity
of the spermatozoon, embryo abnormalities, and pregnancy
complications could potentially have a major impact on
these outcomes. In the same context, protocols including
pretreatments or interventions that could exogenously affect
sperm function were excluded, in an attempt to signify
the value of these tests in a clear-cut manner. Most of the
included studies were published over two decades ago—when
these techniques were considered breakthrough and were
extensively investigated—except that at this period publica-
tion criteria differed significantly, leading to missing crucial
information and statistical reporting methods relying on the
authors’ discretion. This limited our ability to explore the
different approaches of the assay protocols, the efficiency of
the interventions used and participant characteristics to assist
direct comparison and possible attempts to communicate
with the authors for further clarification were abandoned
due to the restricted contact information published at that
point. Moreover, this generated the necessity to recalculate
diagnostic accuracy values wherever the data sets were
available and led to the exclusion of studies that did not report
the appropriate statistical values or corresponding data sets.
A possible limitation could be attributed with regard to cost
efficiency of the particular sperm function tests in practise,
but this parameter was not included in our initial goals
towards investigation as the core purpose of this reviewwas to
clarify the efficiency of these tests in terms of IVF outcome. A
previously published review and meta-analysis [61] explored
various sperm function tests in a similar manner, although
this group did not include the sum of the studies reported
here and no direct comparison was performed between these
two tests to clarify their definite validity on male fertility
investigation. Unavoidably, a number of studies coincide
with Oehninger et al. [61] however, calculation of diagnostic
accuracy values revealed some degree of discordance in terms
of the reported specificity, sensitivity, and PPV and NPV.
Current clinical opinion relies mostly on conventional
semen parameters upon deciding wether to allow natural
conception or to refer for IVF treatment and, quite frequently,
without identifying male fertility potential or any underlying
pathology. Semen analysis is sometimes subject to the evalu-
ators’ individual judgement and has been implicated to exert
limited predictive value in determining sperm function and
fertility potential, as demonstrated by the noted discrepancies
in cases when men with normal semen parameters have
repeated fertilization failure, while men with very abnormal
semen characteristics have fathered children. Some fertility
clinics incorporate sperm function tests in their advanced
investigations, although their clinical significance has been
undermined by the introduction of intracytoplasmic sperm
injection (ICSI), a technique that effectively circumvents
the need for functioning sperm. However, consideration
should be given to ethical and biological aspects; should
natural selection be allowed to take place avoiding the
invasive micromanipulation techniques that mostly rely on
morphology in deciding which spermatozoon is the most fit
to fertilize an oocyte.
Impaired spermatozoa interaction with the zona pellu-
cida and oocyte investments has been classified amongst the
principal causes of fertilization failure, and, in this context,
our data analysis highlighted the validity and high predictive
value of HZA; this result situates this assay within the criteria
for plausibility and applicability of diagnostic tests. From a
clinical perspective, this technically demanding technique
requires an affirmed oocyte source, or the commercial
availability of biologically active human recombinant zona
pellucida, to confront limited oocyte availability. In contrast,
SPA failed to produce uniform results on IVF outcome pre-
diction, and this finding along with protocol inconsistency,
indicate, that it is far from being an absolute test for male
fertility potential. However, more effort should be devoted
in optimizing and reevaluating this technique as a great
advantage of SPA is that this assay utilizes hamster oocytes are
more readily available than human and clinical application of
SPA could possibly be more realistic than implementing an
assay that requires resources which are currently limited.
Ideally, sperm function tests should incorporate a wide
array of functions in a single assay; however, evidence
published to date indicates an apparent dominance of HZA
in the context of clinical significance. Following technical
optimization and establishment of a reliable oocyte source
or analogue availability, HZA could be applied in clinical
practice and could be incorporated as part of a range of tests
for the profiling of gamete functionality. Future technological
advances could promote further improvement of sperm
function tests or even the introduction of a single, conclusive
test on multiple functional aspects for rapid and accurate
diagnosis and optimal clinical management.
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